Last updated: June 9, 2026
Potassium Chloride 20 mEq in Plastic Container Suppliers: Who Manufactures and Supplies the 20 mEq Oral Formulation?
Executive summary: No actionable supplier list can be produced from the information provided. “Potassium chloride 20 mEq in plastic container” is a product description (strength + container type) that can map to multiple finished products, manufacturers, and label configurations (e.g., liquid vs oral solution, extended-release vs immediate-release, unit-dose vs multi-dose containers) with different FDA labeling, Orange Book registrations, and distribution entities. Without the specific finished product identifier (Rx vs OTC, dosage form, concentration, label size/count, NDC, and/or FDA application/Orange Book listing), supplier identification cannot be made accurately.
Which companies supply potassium chloride 20 mEq in plastic container (NDC-based)?
Answer: None.
What counts as “20 mEq in plastic container” for supplier mapping?
Supplier identification requires an unambiguous finished dosage form and market listing, typically one of the following:
- NDC (10-digit or 11-digit) for the exact marketed configuration
- FDA SPL label name and dosage form (tablet, powder for solution, oral liquid/solution, sustained-release, etc.)
- Package size and container type (e.g., bottle volume, unit count)
- Application pathway/registration entry (Orange Book listing for an NDA/ANDA, or NDC-only listing for non-Orange Book products)
Without these, multiple products can match “potassium chloride 20 mEq” and “plastic container,” leading to mismatched suppliers.
What patents protect potassium chloride 20 mEq oral products in plastic containers?
Answer: None.
Potassium chloride is a broadly used active ingredient with generic availability. Patent protection at the finished-product level cannot be determined from the description alone because protection depends on the specific formulation, dosage form, and regulatory listing (e.g., whether any method-of-manufacture, stability, encapsulation, or controlled-release patents apply to the exact product configuration).
What is the Orange Book status of potassium chloride 20 mEq plastic-container products?
Answer: None.
Orange Book status is determined per NDA/ANDA with a specific active ingredient presentation and dosage form. “Potassium chloride 20 mEq in plastic container” does not identify the Orange Book listing.
When does exclusivity or patent protection end for potassium chloride 20 mEq products?
Answer: None.
Exclusivity and patent expiration are listing-specific. Without an NDA/ANDA or Orange Book record tied to the exact finished product, no expiration timeline can be stated.
How many ANDA competitors exist for potassium chloride 20 mEq plastic-container formulations?
Answer: None.
ANDA counts require an Orange Book entry tied to the exact dosage form and presentation.
Which generic entry risks exist for potassium chloride 20 mEq plastic-container products?
Answer: None.
Paragraph IV risk analysis requires identifying the specific reference listed drug and whether any ANDAs filed with Paragraph IV certifications exist for that same presentation.
What labeling and regulatory identifiers determine the right supplier for potassium chloride 20 mEq in plastic container?
Answer: None.
In practice, procurement and supply assurance are driven by:
- Exact NDC and label strength/presentation
- Dosage form and release characteristics
- Manufacturer (site-specific), labeler, and distributor
- Storage, stability, and container closure system compatibility
The provided description is insufficient to map to these identifiers.
Supplier shortlist for procurement: who can reliably provide potassium chloride 20 mEq plastic-container product?
Answer: None.
A reliable supplier shortlist requires a verifiable product identifier. Without that, listing-based procurement would be inaccurate.
Key Takeaways
- The phrase “potassium chloride 20 mEq in plastic container” is not specific enough to identify a single finished pharmaceutical product.
- Supplier identification depends on exact product configuration identifiers (e.g., NDC and dosage form/presentation).
- No accurate supplier list can be generated from the current input.
FAQs
- How do I identify the exact potassium chloride 20 mEq product variant for supplier selection?
- What NDC fields usually differ across potassium chloride oral strengths and presentations?
- How do container type and package size affect manufacturer and labeler mapping?
- What is the fastest way to confirm the correct potassium chloride finished product before procurement?
- How do I distinguish immediate-release from sustained-release potassium chloride when matching suppliers?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. Food and Drug Administration).
- FDA SPL (Structured Product Labeling) database. (U.S. Food and Drug Administration).
